Subscribe to Biological Therapies in Psychiatry -  Choose your plan >
IN THIS MONTH'S ISSUE:
March 2015

A Two-Drug Combination for Weight Loss
The new medication Contrave, which combines the opioid-receptor antagonist naltrexone (ReVia and others) with the antidepressant and smoking cessation compound bupropion (Wellbutrin, Zyban, and others), has been approved as an adjunct to diet and increased exercise for certain overweight and obese patients.

Clozapine Trumps Polypharmacy
For patients with schizophrenia, clozapine (Clozaril and others) is associated with lower costs and reduced disease-specific emergency department use.

In Brief
Brain Activity in Men and Women Differs in Response to Cigarette Smoking; Patients with Anxiety Disorders Are at Greater Risk of Hypertension than the General Population

Lack of Cataracts with Quetiapine
Despite warnings about cataracts, quetiapine (Seroquel) actually appears to have a low risk of causing cataracts.

CME Reminder
March 31, 2015 is the deadline for returning your 2014 CME posttest to earn up to 12.0 hours of category 1 credit.

About the BTP Newsletter

Our subscribers say BTP is…

"Very relevant, practical, and thought-provoking."

"About the only thing left without drug ads...objective and balanced."

"Succinct, readable, clear, timely and relevant!"

"Well written and scientifically sound."

Originating at the Massachusetts General Hospital and Harvard Medical School, Biological Therapies in Psychiatry has been a trusted resource for physicians for over 30 years. Described as "influential" by the Atlantic Monthly, this concise, four-page, monthly newsletter provides up-to-date information about the rapidly expanding field of psychotropic medications and other biological treatments for mental disorders.

From his perspective as an editor, teacher, investigator, and clinician, Alan J. Gelenberg, M.D., reviews the widespread literatures of science and clinical practice. Dr. Gelenberg distills the material most relevant for a busy practitioner and presents it each month with a balance of scientific curiosity, healthy skepticism, and clinical experience.

Dr. Gelenberg is Professor and Interim Chair of Psychiatry at Penn State, Hershey. Since 1987, Dr. Gelenberg has been Editor-in-Chief of the Journal of Clinical Psychiatry, and he recently chaired the workgroup that revised the American Psychiatric Association's major depressive disorder guidelines. Dr. Gelenberg has been on the faculty of Harvard Medical School, MIT, and the University of Arizona and has written numerous scientific articles and book chapters on mood disorders, depression, and schizophrenia. He is listed in the Best Doctors in America and America's Top Doctors and received the 1997 Exemplary Psychiatrist Award of the National Alliance for the Mentally Ill.

We offer both print and online subscriptions. Our web site provides subscribers with 24-hour access to archives as well as current issues. In addition, Continuing Medical Education credit is available for reading BTP. You can earn up to 12.0 hours in category 1 credit by answering questions in the December issue about topics covered during the year.